Skip to main content

Hereditary Cancer Counseling and Germline Genetic Testing

  • 254 Accesses

Abstract

Screening for inherited predisposition to cancer and germline genetic testing are part of the standard of care for breast cancer management, with implications for immediate and survivorship management. The advent of multigene next-generation sequencing panels has increased the complexity of testing while also making it less expensive. The dynamic nature of genetic knowledge and testing technology necessitates ongoing assessment for new or updated genetics evaluation throughout survivorship to maximize the reduction of cancer morbidity and mortality.

Keywords

  • Hereditary cancer counseling
  • Cancer predisposition
  • Genetics
  • Germline
  • Mutations
  • Next-generation sequencing (NGS)

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-75377-1_20
  • Chapter length: 13 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-75377-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   119.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Fig. 20.1

References

  1. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomaki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg A, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkas K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmana J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020;38(7):674–85. Epub 2019/12/17. https://doi.org/10.1200/JCO.19.01907. PubMed PMID: 31841383; PMCID: PMC7049229.

  2. Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, Waisfisz Q, Hollestelle A, Schutte M, van den Ouweland A, Hooning M, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Arndt V, Bermisheva M, Bogdanova NV, Bolla MK, Brauch H, Brenner H, Bruning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Couch FJ, Cox A, Cross SS, Czene K, Dunning AM, Fasching PA, Figueroa J, Fletcher O, Flyger H, Galle E, Garcia-Closas M, Giles GG, Haeberle L, Hall P, Hillemanns P, Hopper JL, Jakubowska A, John EM, Jones M, Khusnutdinova E, Knight JA, Kosma VM, Kristensen V, Lee A, Lindblom A, Lubinski J, Mannermaa A, Margolin S, Meindl A, Milne RL, Muranen TA, Newcomb PA, Offit K, Park-Simon TW, Peto J, Pharoah PD, Robson M, Rudolph A, Sawyer EJ, Schmutzler RK, Seynaeve C, Soens J, Southey MC, Spurdle AB, Surowy H, Swerdlow A, Tollenaar RA, Tomlinson I, Trentham-Dietz A, Vachon C, Wang Q, Whittemore AS, Ziogas A, van der Kolk L, Nevanlinna H, Dork T, Bojesen S, Easton DF. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750–60. Epub 2016/06/09. https://doi.org/10.1200/JCO.2016.66.5844. PubMed PMID: 27269948; PMCID: PMC5019754 online at www.jco.org. Author contributions are found at the end of this article.

  3. Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, Godwin AK, Konstantopoulou I, Nevanlinna H, Sharma P, Yannoukakos D, Yao S, Feng BJ, Tippin Davis B, Lilyquist J, Pesaran T, Goldgar DE, Polley EC, Dolinsky JS, Couch FJ. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018;110(8):855–62. Epub 2018/08/14. https://doi.org/10.1093/jnci/djy106. PubMed PMID: 30099541; PMCID: PMC6093350.

  4. Petridis C, Arora I, Shah V, Moss CL, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ. Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(7):1162–8. Epub 2019/07/03. https://doi.org/10.1158/1055-9965.EPI-18-1102.

    CAS  CrossRef  PubMed  Google Scholar 

  5. Network NCC. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2021 2020 [cited 2020 Octover 11]. Available from: https://www.nccn.org/.

  6. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM, Syngal S, Wollins DS, Lindor NM. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660–7. https://doi.org/10.1200/jco.2015.63.0996.

    CAS  CrossRef  PubMed  Google Scholar 

  7. Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS. Germline genetic testing: what the breast surgeon needs to Know. Annals of Surgical Oncology. 2019;26(7):2184–90. https://doi.org/10.1245/s10434-019-07341-8.

    CrossRef  PubMed  Google Scholar 

  8. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng C-W, Wong JB. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA. 2019;322(7):652. https://doi.org/10.1001/jama.2019.10987.

    CrossRef  PubMed  Google Scholar 

  9. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38(18):2080–106. https://doi.org/10.1200/jco.20.00299.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Annals Surg Oncol. 2019;26(10):3025–31. https://doi.org/10.1245/s10434-019-07549-8.

    CrossRef  Google Scholar 

  11. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Nat Comprehen Cancer Network. 2020;18(4):380–91. https://doi.org/10.6004/jnccn.2020.0017.

  12. Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncology. 2018;4(8):1066. https://doi.org/10.1001/jamaoncol.2018.0644.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  13. Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman A-R, Winer EP, Garber JE. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8. https://doi.org/10.1200/jco.2015.65.0747.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  14. Gustafson SL, Raymond VM, Marvin ML, Else T, Koeppe E, Stoffel EM, Everett JN. Outcomes of genetic evaluation for hereditary cancer syndromes in unaffected individuals. Fam Cancer. 2015;14(1):167–74. Epub 2014/09/24. https://doi.org/10.1007/s10689-014-9756-x.

    CrossRef  PubMed  Google Scholar 

  15. Forbes C, Fayter D, De Kock S, Quek RGW. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manage Res. 2019;11:2321–37. https://doi.org/10.2147/cmar.s189627.

    CrossRef  Google Scholar 

  16. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, Lamonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611–35. https://doi.org/10.1200/jco.2015.64.3809.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531. https://doi.org/10.1001/jama.2016.16918.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  18. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B, Robbertse B, Smith-White B, Ako-Adjei D, Astashyn A, Badretdin A, Bao Y, Blinkova O, Brover V, Chetvernin V, Choi J, Cox E, Ermolaeva O, Farrell CM, Goldfarb T, Gupta T, Haft D, Hatcher E, Hlavina W, Joardar VS, Kodali VK, Li W, Maglott D, Masterson P, McGarvey KM, Murphy MR, O'Neill K, Pujar S, Rangwala SH, Rausch D, Riddick LD, Schoch C, Shkeda A, Storz SS, Sun H, Thibaud-Nissen F, Tolstoy I, Tully RE, Vatsan AR, Wallin C, Webb D, Wu W, Landrum MJ, Kimchi A, Tatusova T, Dicuccio M, Kitts P, Murphy TD, Pruitt KD. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016;44(D1):D733–D45. https://doi.org/10.1093/nar/gkv1189.

  19. Myriad Genetics I. 2020 [updated September 3, 2020; cited 2020 October 26, 2020. Technical sheet for Myriad testing]. Available from: https://s3.amazonaws.com/myriad-library/technical-specifications/BRCA+Tech+Specs_Integrated.pdf.

  20. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics Med. 2015;17(5):405–23. https://doi.org/10.1038/gim.2015.30.

    CrossRef  Google Scholar 

  21. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho Y-Y, Kobayashi Y, Patil N, Thusberg J, Westbrook M, Topper S. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria. Genetics Med. 2017;19(10):1105–17. https://doi.org/10.1038/gim.2017.37.

    CrossRef  Google Scholar 

  22. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A, McDaniel K, Ovetsky M, Riley G, Zhou G, Kattman BL, Maglott DR. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–D7. https://doi.org/10.1093/nar/gkx1153.

    CAS  CrossRef  PubMed  Google Scholar 

  23. Nussbaum RL, Yang S, Lincoln SE. Clinical genetics testing laboratories have a remarkably low rate of clinically significant discordance when interpreting variants in hereditary cancer syndrome genes2017. JCO. 2016;70:945. https://doi.org/10.1200/jco.2016.70.9451

  24. Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Yin Lam AK, Gopalan V. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J Cell Physiol. 2018; https://doi.org/10.1002/jcp.27464.

  25. Taeubner J, Wieczorek D, Yasin L, Brozou T, Borkhardt A, Kuhlen M. Penetrance and expressivity in inherited cancer predisposing syndromes. Trends in Cancer. 2018;4(11):718–28. https://doi.org/10.1016/j.trecan.2018.09.002.

    CAS  CrossRef  PubMed  Google Scholar 

  26. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genetics Med. 2011;13(2):148–54. https://doi.org/10.1097/gim.0b013e318207f564.

    CrossRef  Google Scholar 

  27. Witt MM, Witt MP. Privacy and confidentiality measures in genetic testing and counselling: arguing on genetic exceptionalism again? J Appl Genetics. 2016;57(4):483–5. https://doi.org/10.1007/s13353-016-0339-4.

    CrossRef  Google Scholar 

  28. Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020;38(14):1539–48. https://doi.org/10.1200/jco.19.03292.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, Von Minckwitz G, Schmutzler RK. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer. JAMA Oncol. 2017;3(10):1378. https://doi.org/10.1001/jamaoncol.2017.1007.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  30. Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, Von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509. https://doi.org/10.1016/s1470-2045(18)30111-6.

    CAS  CrossRef  PubMed  Google Scholar 

  31. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–80. https://doi.org/10.1016/s1470-2045(17)30891-4.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  32. Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay inBRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer. 2016;122(8):1178–84. https://doi.org/10.1002/cncr.29903.

    CAS  CrossRef  PubMed  Google Scholar 

  33. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, Desnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388–94. https://doi.org/10.1200/jco.19.01304.

    CAS  CrossRef  PubMed  Google Scholar 

  34. Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119(2):141–52. https://doi.org/10.1038/s41416-018-0127-5.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  35. Jagsi R, Griffith KA, Kurian AW, Morrow M, Hamilton AS, Graff JJ, Katz SJ, Hawley ST. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol. 2015;33(14):1584–91. https://doi.org/10.1200/jco.2014.58.5885.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  36. Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42(16):2722–8. Epub 2006/09/05. https://doi.org/10.1016/j.ejca.2006.05.032.

    CrossRef  PubMed  Google Scholar 

  37. Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531-4. Epub 2017/02/09. https://doi.org/10.1001/jama.2016.16918. PubMed PMID: 28170472; PMCID: PMC5530866.

  38. MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). The Lancet. 2005;365(9473):1769–78. https://doi.org/10.1016/s0140-6736(05)66481-1.

    CrossRef  Google Scholar 

  39. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117(17):3900–7. Epub 2011/03/03. https://doi.org/10.1002/cncr.25971.

    CrossRef  PubMed  Google Scholar 

  40. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Magnetic Resonance Imaging Screening Study G. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427–37. Epub 2004/07/30. https://doi.org/10.1056/NEJMoa031759.

    CAS  CrossRef  PubMed  Google Scholar 

  41. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664-9. Epub 2011/03/30. https://doi.org/10.1200/JCO.2009.27.0835. PubMed PMID: 21444874; PMCID: PMC4874196.

  42. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295(20):2374–84. Epub 2006/05/25. https://doi.org/10.1001/jama.295.20.2374.

    CAS  CrossRef  PubMed  Google Scholar 

  43. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.

    CrossRef  Google Scholar 

  44. Roberts MC, Dusetzina SB. The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. 2017. https://doi.org/10.1007/s12687-017-0295-7.

  45. Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, Bartels CCM, Verhoog LC, van den Ouweland AMW, Niermeijer MF, Brekelmans CTM, Klijn JGM. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New England J Med. 2001;345(3):159–64.

    Google Scholar 

  46. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van’T Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–62. https://doi.org/10.1200/jco.2004.04.188.

    CrossRef  PubMed  Google Scholar 

  47. Kauff ND, Robson ME, Offit K. Oophorectomy in carriers of BRCA mutations. New England J Med. 2002;347(13):1037–40.

    Google Scholar 

  48. Van Der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Chelcun Schreiber KE, Hardwick RH, Ausems MGEM, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, Degregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJL, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe STA, Van Dijck B, Van Grieken NCT, Van Hillegersberg R, Van Sandick JW, Vehof R, Van Krieken JH, Fitzgerald RC. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. J Med Genet. 2015;52(6):361–74. https://doi.org/10.1136/jmedgenet-2015-103094.

  49. Milas M, Mester J, Metzger R, Shin J, Mitchell J, Berber E, Siperstein AE, Eng C. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery. 2012;152(6):1201–10. https://doi.org/10.1016/j.surg.2012.08.055.

    CrossRef  PubMed  Google Scholar 

  50. Myriad. Myriad Introduces Enhanced BRACAnalysis® Test for Exceptionally High-Risk Breast Cancer Patients. Myriad Genetics, Inc; 2006.

    Google Scholar 

  51. Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-generation sequencing in breast cancer. 2012;24(6):597–604. https://doi.org/10.1097/cco.0b013e328359554e.

  52. Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, Aston M, Esterling L, Manley S, Ross T. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA. 2018;320(12):1266. https://doi.org/10.1001/jama.2018.13152.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  53. Lyra PCM, Nepomuceno TC, De Souza MLM, Machado GF, Veloso MF, Henriques TB, Dos Santos DZ, Ribeiro IG, Ribeiro RS, Rangel LBA, Richardson M, Iversen ES, Goldgar D, Couch FJ, Carvalho MA, Monteiro ANA. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. Genetics Med. 2020; https://doi.org/10.1038/s41436-020-00991-0.

  54. Turner SA, Rao SK, Morgan RH, Vnencak-Jones CL, Wiesner GL. The impact of variant classification on the clinical management of hereditary cancer syndromes. Genetics Med. 2019;21(2):426–30. https://doi.org/10.1038/s41436-018-0063-z.

    CrossRef  Google Scholar 

  55. Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England J Med. 2017;377(6):523–33. https://doi.org/10.1056/nejmoa1706450.

    CAS  CrossRef  Google Scholar 

  56. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im Y-H, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England J Med. 2018;379(8):753–63. https://doi.org/10.1056/nejmoa1802905.

    CAS  CrossRef  Google Scholar 

  57. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehen Cancer Network. 2020;18(4):452–78. https://doi.org/10.6004/jnccn.2020.0016.

  58. Storm C, Agarwal R, Offit K. Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? J Oncol Pract. 2008;4(5):229–30. https://doi.org/10.1200/jop.0858504.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  59. Rothstein MA. Reconsidering the duty to warn genetically at-risk relatives. Genetics Med. 2018;20(3):285–90. https://doi.org/10.1038/gim.2017.257.

    CrossRef  Google Scholar 

  60. Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank SV, Caputo TA, Sharaf RN, Offit K, Holcomb K, Lipkin S. Prospective feasibility trial of a novel strategy of facilitated cascade genetic testing using telephone counseling. J Clin Oncol. 2020;38(13):1389–97. https://doi.org/10.1200/jco.19.02005.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  61. Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S. Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening. J Clin Oncol. 2020;38(13):1398–408. https://doi.org/10.1200/jco.19.02010.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carolyn Menendez .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Menendez, C., Marcom, P.K., Sutton, L.M. (2021). Hereditary Cancer Counseling and Germline Genetic Testing. In: Kimmick, G.G., Shelby, R.A., Sutton, L.M. (eds) Common Issues in Breast Cancer Survivors. Springer, Cham. https://doi.org/10.1007/978-3-030-75377-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75377-1_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75376-4

  • Online ISBN: 978-3-030-75377-1

  • eBook Packages: MedicineMedicine (R0)